1,721,578 research outputs found
Gentuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and esistance, safety and efficacy.
No full textArsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease
No full text
Hybrid phenotypes and lineage promiscuity in acute leukemia
No full textClinical data indicate that AL are heterogeneous diseases with variable responsiveness to chemotherapeutic agents. Based on this evidence, the efforts of most investigators are aimed at providing rapid identification of AL features predictive of distinct prognostic outcomes. A considerable number of reagents (including MoAb and molecular probes) available from commercial sources has been widely used for diagnostic purpose, leading to the identification of "inappropriate" antigen expression and to diagnoses of "mixed" AL (M-AL). The latter still lacks adequate definition and identification criteria, but is frequently reported as a novel entity associated with poor clinical outcome. The use of more accurate methodologic approaches, as well as a better elucidation of normal hemopoietic cell characteristics suggest that true M-AL occur quite rarely: the features of normal precursor counterparts are more frequently conserved. "Ectopic" marker expression, however, which should not be interpreted as reflecting lineage infidelity, may in some instances explain different clinical courses in AL patients. Further elucidation of normal stem cell features, and adequate standardization of AL immunophenotyping--to be performed under proper technical conditions--are needed for a better evaluation of M-AL, both in terms of diagnosis and classification, as well as regarding their clinical significance
Additive effects in the induction of apoptosis in leukemic cells by WT1 and BCR-ABL specific siRNA
No full text
Body cavity lymphoma.
No full textBody cavity lymphomas (BCLs) are a heterogeneous group of rare, primary non-Hodgkin's lymphomas that proliferate within the serous body cavities and result in recurrent effusions. This review is mainly focussed on the distinct entity primary effusion lymphoma (PEL) wherein the tumor clone is infected by human herpesvirus-8, the etiologic agent of Kaposi's sarcoma. In addition, we briefly discuss here recent data regarding other BCL types. The latter include a subset with no evidence of herpesvirus 8 which is associated with Epstein-Barr virus (pyothorax-associated lymphoma, PAL), the BCL forms associated to hepatitis C virus-related cirrhosis or alcohol-related cirrhosis and, finally, non-neoplastic forms mimicking lymphomatous effusions
ATRA plus ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?
No full text
- …
